Equillium Raises $30M Via Equity, Shares Rally


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • Equillium Inc (NASDAQ: EQ) has entered into a securities purchase agreement with Decheng Capital to purchase around 4.3 million units from Equillium at $7 per unit, equivalent to gross proceeds of $30 million. EQ's closing price as of Wednesday was $6.62 per share.
  • Each unit consists of one common stock and a warrant to purchase 0.3 of common stock. The five-year warrants will have an exercise price of $14 per share.
  • Net proceeds will be used to primarily fund the development of the itolizumab pipeline, potential acquisitions and development of new products, and for working capital and general corporate purposes.
  • The direct offering is expected to close by February 5.
  • Price Action: EQ shares are trading higher by 19.2% at $7.90 on the last check Thursday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsOfferingsGeneral